why choose us

First received: August 15, 2023

Clinical Trial: Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder

Study Status: Completed

Recruit Status: RECRUITING

Condition: Opioid Use Disorder

Study Type: INTERVENTIONAL


Official Title: Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind Trial

Brief Summary: This study will examine the effect of a single high dose of psilocybin therapy (30 mg) versus a very low dose (1 mg) as an adjunctive therapy to individuals undergoing standard-of-care buprenorphine treatment for Opioid use disorder (OUD).Effects of adjunctive psilocybin will be determined for longitudinal outcomes of opioid abstinence, compliance with buprenorphine maintenance, quality of life, and mood.

Read more